<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280266</url>
  </required_header>
  <id_info>
    <org_study_id>RaynaudSNUH</org_study_id>
    <nct_id>NCT01280266</nct_id>
  </id_info>
  <brief_title>Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon</brief_title>
  <official_title>Comparison of Phosphodiesterase-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon, Double Blind, Randomized, Cross-over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      The prevalence of Raynaud phenomenon (RP), a reversible vaso-constriction with skin
      discoloration, is 5-10% in general population. Often conventional measures such as warming up
      or minimizing exposure to cold are not enough and many patients require treatment with a
      vasodilator therapy. A recent study showed a good efficacy and safety profile of sildenafil,
      a selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in RP.

      Here, the investigators aim to examine the efficacy and safety of Udenafil, a newer PDE5
      inhibitor, as compared to amlodipine, a well known calcium channel blocker, in the treatment
      of secondary RP in Korean patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RP Attacks Per Day</measure>
    <time_frame>baselin and 4 weeks</time_frame>
    <description>Change in RP frequency after amlodipine and udenafil number of RP attack per day 0 -- unlimited.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Raynaud's Condition Score (RCS)</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>change in the RCS. RCS combines daily activty, frequency, duration and severity as well as impact of RP attack (Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon, Merkel et al,Arthritis Rheum. 2002 Sep;46(9):2410-20).
Range 0-10 ordinal scale 0..good 10.. bad</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the RP Duration</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>Change in the average RP duration in minutes (min) per attack. 0 -- unlimited</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health Assessment Questionnaire (HAQ)</measure>
    <time_frame>0 and 4 weeks</time_frame>
    <description>Ordinal scale 0-10 0 good 10 bad</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physician's Global Assessment on Visual Analogue Scale (VAS)</measure>
    <time_frame>at 0 (baseline) and 4 weeks (after treatment)</time_frame>
    <description>Physician's global assessment (PGA) on VAS assesses the overall condition of the patient. The scale ranges from 0 - 10, with 0 being good and 10 bad. As such, change in the GPA measures the change in the patient's condition from the baseline.
negative value (decrease in value) means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Digital Ulcer Number</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>0 - unlimited. Number of digital ulcers in all fingers are counted by the investigators and recorded at each visit. The number of ulcers in all fingers indirectly reflect the extent of critical ischemia. As such. the decrease in digital ulcer number reflects positive response to treatment (=better blood flow), whereas the increase ulcer numbers indicates worsening finger ischemia from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Systolic Flow (cm/Sec)</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>Change in digital artery flow velocity in proper palmar digital artery in cm/sec.
0-unlimited</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-averaged Peak Velocity (cm/Sec)</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>changes in the averaged blood flow (Time-averaged peak velocity) Blood flow in cm/sec 0 - unlimited.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dorsal-digital-difference.</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>The temperature difference between finger tips and dorsum of same hand. range 0 - unlimited in degree celcius.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Raynaud Phenomenon</condition>
  <arm_group>
    <arm_group_label>Amlodipine-Udenafil (AU) arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 10mg PO QD for 4 weeks, washout period, then Udenafil 100mg PO QD for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Udenafil-Amlodipine (UA) arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Udenafil 100mg PO QD for 4 weeks, washout period, then Amlodipine 10mg PO QD for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Udenafil or Amlodipine</intervention_name>
    <description>Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily</description>
    <arm_group_label>Amlodipine-Udenafil (AU) arm</arm_group_label>
    <arm_group_label>Udenafil-Amlodipine (UA) arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  secondary Raynaud's phenomenon

        Exclusion Criteria:

          -  primary raynaud phenomenon

          -  active infection

          -  hypersensitivity to PDE5 inhibitor or Calcium Chanel Blocker (CCB)

          -  elevated AST/ALT (3 times above the upper normal limit)

          -  severe renal failure

          -  patients on nitrite or nitric oxide (NO) donor treatment

          -  recent history of cerebrovascular accidents, acute myocardial infarction, or coronary
             artery bypass surgery

          -  hypotension (less than 90/50 mmHg) or uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eun Bong Lee, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>professor of Seoul National University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eun Young Lee, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistant professor, Seoul National University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Kyun Park, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2011</study_first_posted>
  <results_first_submitted>July 4, 2012</results_first_submitted>
  <results_first_submitted_qc>December 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 11, 2012</results_first_posted>
  <last_update_submitted>December 7, 2012</last_update_submitted>
  <last_update_submitted_qc>December 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Eun Bong Lee</investigator_full_name>
    <investigator_title>Direct, Division of Rheumatology</investigator_title>
  </responsible_party>
  <keyword>Pathological Conditions</keyword>
  <keyword>Signs and Symptoms</keyword>
  <keyword>Blood circulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raynaud Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Udenafil</mesh_term>
    <mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment begin Jan 13 2011 until Mar 15 2011. Location: Rheumatology outpatient clinic at Seoul National University Hospital, Seoul, Korea.</recruitment_details>
      <pre_assignment_details>30 Patients were initially recruited, but an error occurred in obtaining informed consent and this one was withdrawn.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Amlodipine-Udenafil (AU) Arm</title>
          <description>Amlodipine 10mg PO QD for 4 weeks, washout period for 1week, then Udenafil 100mg PO QD for 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Udenafil-Amlodipine (UA) Arm</title>
          <description>Udenafil 100mg PO QD for 4 weeks, washout period for 1 week, then Udenafil 10mg PO QD for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (Week 1-4)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period (Week 4-5)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (Week 5-9)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amlodipine-Udenafil (AU) Arm</title>
          <description>Amlodipine first, then Udenafil</description>
        </group>
        <group group_id="B2">
          <title>Udenafil-Amlodipine (UA) Arm</title>
          <description>Udenafil first, then Amlodipine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="14.0"/>
                    <measurement group_id="B2" value="52.3" spread="10.3"/>
                    <measurement group_id="B3" value="50.9" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease subtype</title>
          <description>Underlying rheumatic disease</description>
          <units>participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Localized systemic sclerosis (SSc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diffuse SSc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed connective tissue disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sjogren's disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>RP duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.8" spread="8.7"/>
                    <measurement group_id="B2" value="5.6" spread="2.3"/>
                    <measurement group_id="B3" value="7.3" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior use of vasodilator</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>calcium channel blocker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>angiotensin receptor blocker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pentyxifylline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No prior use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>RP Attacks Per Day</title>
        <description>Change in RP frequency after amlodipine and udenafil number of RP attack per day 0 -- unlimited.</description>
        <time_frame>baselin and 4 weeks</time_frame>
        <population>14 patients in UA arm + 12 patients in AU arm</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine</title>
            <description>Changes in RP attacks per day during amlodipine 10 mg orally per day</description>
          </group>
          <group group_id="O2">
            <title>Udenafil</title>
            <description>Changes in RP attacks per day during udenafil 100mg orally per day</description>
          </group>
        </group_list>
        <measure>
          <title>RP Attacks Per Day</title>
          <description>Change in RP frequency after amlodipine and udenafil number of RP attack per day 0 -- unlimited.</description>
          <population>14 patients in UA arm + 12 patients in AU arm</population>
          <units>attacks per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.4"/>
                    <measurement group_id="O2" value="-0.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Raynaud's Condition Score (RCS)</title>
        <description>change in the RCS. RCS combines daily activty, frequency, duration and severity as well as impact of RP attack (Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon, Merkel et al,Arthritis Rheum. 2002 Sep;46(9):2410-20).
Range 0-10 ordinal scale 0..good 10.. bad</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine</title>
            <description>Changes in RPS during amlodipine 100 mg orally per day</description>
          </group>
          <group group_id="O2">
            <title>Udenafil</title>
            <description>Changes in RPS during udenafil 10 mg orally per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Raynaud's Condition Score (RCS)</title>
          <description>change in the RCS. RCS combines daily activty, frequency, duration and severity as well as impact of RP attack (Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon, Merkel et al,Arthritis Rheum. 2002 Sep;46(9):2410-20).
Range 0-10 ordinal scale 0..good 10.. bad</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.5"/>
                    <measurement group_id="O2" value="-0.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the RP Duration</title>
        <description>Change in the average RP duration in minutes (min) per attack. 0 -- unlimited</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine</title>
            <description>Drug: amlodipine 100 mg p.o. per day</description>
          </group>
          <group group_id="O2">
            <title>Udenafil</title>
            <description>Drug: udenafil 10 mg p.o. per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the RP Duration</title>
          <description>Change in the average RP duration in minutes (min) per attack. 0 -- unlimited</description>
          <units>min per attack</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="5.9"/>
                    <measurement group_id="O2" value="-1.4" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Health Assessment Questionnaire (HAQ)</title>
        <description>Ordinal scale 0-10 0 good 10 bad</description>
        <time_frame>0 and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine</title>
            <description>Drug: amlodipine 100 mg p.o. per day</description>
          </group>
          <group group_id="O2">
            <title>Udenafil</title>
            <description>Drug: udenafil 10 mg p.o. per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Health Assessment Questionnaire (HAQ)</title>
          <description>Ordinal scale 0-10 0 good 10 bad</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.4"/>
                    <measurement group_id="O2" value="-0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physician's Global Assessment on Visual Analogue Scale (VAS)</title>
        <description>Physician's global assessment (PGA) on VAS assesses the overall condition of the patient. The scale ranges from 0 - 10, with 0 being good and 10 bad. As such, change in the GPA measures the change in the patient's condition from the baseline.
negative value (decrease in value) means improvement.</description>
        <time_frame>at 0 (baseline) and 4 weeks (after treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine</title>
            <description>Drug: amlodipine 100 mg p.o. per day</description>
          </group>
          <group group_id="O2">
            <title>Udenafil</title>
            <description>Drug: udenafil 10 mg p.o. per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physician's Global Assessment on Visual Analogue Scale (VAS)</title>
          <description>Physician's global assessment (PGA) on VAS assesses the overall condition of the patient. The scale ranges from 0 - 10, with 0 being good and 10 bad. As such, change in the GPA measures the change in the patient's condition from the baseline.
negative value (decrease in value) means improvement.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.4"/>
                    <measurement group_id="O2" value="-1.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Digital Ulcer Number</title>
        <description>0 - unlimited. Number of digital ulcers in all fingers are counted by the investigators and recorded at each visit. The number of ulcers in all fingers indirectly reflect the extent of critical ischemia. As such. the decrease in digital ulcer number reflects positive response to treatment (=better blood flow), whereas the increase ulcer numbers indicates worsening finger ischemia from baseline.</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine</title>
            <description>Drug: amlodipine 100 mg p.o. per day</description>
          </group>
          <group group_id="O2">
            <title>Udenafil</title>
            <description>Drug: udenafil 10 mg p.o. per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Digital Ulcer Number</title>
          <description>0 - unlimited. Number of digital ulcers in all fingers are counted by the investigators and recorded at each visit. The number of ulcers in all fingers indirectly reflect the extent of critical ischemia. As such. the decrease in digital ulcer number reflects positive response to treatment (=better blood flow), whereas the increase ulcer numbers indicates worsening finger ischemia from baseline.</description>
          <units>Digital ulcers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.4"/>
                    <measurement group_id="O2" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peak Systolic Flow (cm/Sec)</title>
        <description>Change in digital artery flow velocity in proper palmar digital artery in cm/sec.
0-unlimited</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine</title>
            <description>Drug: amlodipine 100 mg p.o. per day</description>
          </group>
          <group group_id="O2">
            <title>Udenafil</title>
            <description>Drug: udenafil 10 mg p.o. per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Systolic Flow (cm/Sec)</title>
          <description>Change in digital artery flow velocity in proper palmar digital artery in cm/sec.
0-unlimited</description>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.9" spread="145.9"/>
                    <measurement group_id="O2" value="63.2" spread="170.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-averaged Peak Velocity (cm/Sec)</title>
        <description>changes in the averaged blood flow (Time-averaged peak velocity) Blood flow in cm/sec 0 - unlimited.</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine</title>
            <description>Drug: amlodipine 100 mg p.o. per day</description>
          </group>
          <group group_id="O2">
            <title>Udenafil</title>
            <description>Drug: udenafil 10 mg p.o. per day</description>
          </group>
        </group_list>
        <measure>
          <title>Time-averaged Peak Velocity (cm/Sec)</title>
          <description>changes in the averaged blood flow (Time-averaged peak velocity) Blood flow in cm/sec 0 - unlimited.</description>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.3" spread="98.6"/>
                    <measurement group_id="O2" value="33.4" spread="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dorsal-digital-difference.</title>
        <description>The temperature difference between finger tips and dorsum of same hand. range 0 - unlimited in degree celcius.</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine</title>
            <description>Drug: amlodipine 100 mg p.o. per day</description>
          </group>
          <group group_id="O2">
            <title>Udenafil</title>
            <description>Drug: udenafil 10 mg p.o. per day</description>
          </group>
        </group_list>
        <measure>
          <title>Dorsal-digital-difference.</title>
          <description>The temperature difference between finger tips and dorsum of same hand. range 0 - unlimited in degree celcius.</description>
          <units>degree celcius.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="3.2"/>
                    <measurement group_id="O2" value="-1.4" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During 8 weeks while taking a study drug.</time_frame>
      <desc>As a cross over trial, study participants received both amlodipine and udenafil following each other.</desc>
      <group_list>
        <group group_id="E1">
          <title>Amlodipine</title>
          <description>Adverse effects observed while taking amlodipine in both study arms</description>
        </group>
        <group group_id="E2">
          <title>Udenafil</title>
          <description>Adverse effects observed while taking udenafil in both study arms</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Facial edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Facial flushing</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Facial edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eun Bong Lee</name_or_title>
      <organization>Seoul National University</organization>
      <phone>+82 2 2072-3944</phone>
      <email>leb7616@snu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

